Repligen corporation released its second quarter financial results including a very brief overview of its current research.
The company is researching the drug candidate formerly known as Quinazoline495, now known as RG3039. The report states: "During the quarter we enrolled 24 subjects in a Phase 1 clinical study of RG3039 in healthy volunteers. To date there have been no serious adverse events in any subject."
RG3039 was initally funded and its preclinical development work directed by the Families of SMA, their investment being more than $13 million prior to licensing RG3039 to Repligen.
The company is researching the drug candidate formerly known as Quinazoline495, now known as RG3039. The report states: "During the quarter we enrolled 24 subjects in a Phase 1 clinical study of RG3039 in healthy volunteers. To date there have been no serious adverse events in any subject."
RG3039 was initally funded and its preclinical development work directed by the Families of SMA, their investment being more than $13 million prior to licensing RG3039 to Repligen.
Comments
Post a Comment